Mode
Text Size
Log in / Sign up
N/A N=29 Randomized Supportive Care

Expressing Personal Recollections in English or Spanish to Alleviate Traumatic Emotions (Exprésate)

Post Traumatic Stress Disorder

Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Change in PTSD Symptoms as Assessed by the Impact of Event Scale — -.383; 6.43; -3.18; -2.11 score on a scale — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Weekly Emotional Disclosure (WED) (Behavioral); Weekly Emotional Disclosure (WED) Spanish (Behavioral)
Age
Adult, Older Adult · 21+ yrs
Sex
Female
Sponsor
University of Miami
Primary completion
Feb 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in PTSD Symptoms as Assessed by the Impact of Event Scale
-.383; 6.43; -3.18; -2.11 <0.05 sig
PRIMARY
Changes in Verbal Learning as Assessed by Hopkins Verbal Learning Task
10.43; 11.67; 12; 9.80
SECONDARY
Change in Functional Activity of the Default Mode Network (DMN).
.702; -.716; -.225; -.118 <0.05 sig
SECONDARY
Change in Salivary Measures of Stress Reactivity.
-871.9; -250.87; -622.3; -129.53 <0.05 sig

Summary

The purpose of this study is to test if expressive writing about traumatic events has positive changes in women living with post-traumatic stress.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 21 years
  • Elevated PTSD symptoms as assessed by the Post-Traumatic Stress Disorder Checklist Scale-Version DSM 5 (PCL-5) using a cut-off of 34 or above
  • On a stable anti-retroviral therapy regimen for > 6 months as assessed with the Adult AIDS Clinical Trial Group structured interview
  • Spanish-English bilingual as measured by the Brief Acculturation Scale for Hispanics (cut-off of 3), Spanish speaker or English speaker
  • Participant is willing and able to sign Informed Consent Form (ICF)
  • self-report as Latina
  • HIV positive serostatus as determined by medical record within the last 12 months
  • Born female.

Exclusion Criteria

  • Left-handedness or ambidextrous
  • Inability to tolerate the scanning procedures
  • Metal in body or prior history working with metal fragments
  • Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body)
  • currently pregnant or could be pregnant
  • Heavy alcohol intake (> 3 drinks) within 12 hours prior to participation in Functional Magnetic Resonance Imaging (fMRI)
  • Evidence from health history of neurological or systemic disorder which can cause cognitive impairment
  • Self-reported current diagnosis of psychiatric disorder or psychoactive substance abuse or dependence
  • Recent history (within two years) of myocardial infarction
  • Severe cardiovascular disease, or currently active cardiovascular disease (e.g., angina, cardiomyopathy)
  • Uncontrolled hypertension or hypotension
  • History of closed trauma with loss of consciousness
  • Space occupying lesions (e.g., mass lesions, tumors)
  • Central Nervous System (CNS) infection
  • CNS vasculitis
  • CNS demyelinating disease (e.g., multiple sclerosis)
  • Congenital CNS abnormality (e.g., cerebral palsy)
  • Seizure disorders
  • History of cerebrovascular disease (e.g., stroke, TIA's)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05090839). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search